A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
1actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision; the decision is not related to any safety concern.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-18 | actual | When the study began enrolling |
| Primary completion | 2026-06-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-02 | actual | The whole study's end, after follow-up |
| First posted | 2026-01-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Spontaneous Urticaria
Intervention
- Drug: Dupilumab
Primary outcomes
what the primary-completion date above is the date OFSummary of Sociodemographic Characteristics
measured Baseline
Summary of Medical History of Chronic Spontaneous Urticaria (CSU)
measured Baseline
Summary of Type of Baseline Comorbidities
measured Baseline
Summary of Type of Concomitant Medication
measured Baseline
Summary of Healthcare Provider Specialties
measured Baseline
Summary of Dupilumab Dosing Regimen
measured Baseline
Summary of Treatments Used After Discontinuation
measured Baseline
Summary of Participants Re-treated with Dupilumab and Reason
measured Baseline
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed